Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden - Takeaways - MDSpire

Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden

  • By

  • Xiang-Ning Cheng

  • Liu-Qing Zhou

  • Yue Zhou

  • Sha-Zhou Li

  • Shan Chen

  • Qing Cheng

  • Li-Yue Li

  • Jian-Jun Chen

  • Tao Zhou

  • June 11, 2026

  • 0 min

Share

  • 1

    Stapokibart is a humanized anti-IL-4 receptor alpha antibody evaluated for efficacy in patients with chronic rhinosinusitis with nasal polyps.

  • 2

    In a study of 40 patients, stapokibart significantly improved olfactory function by Week 2, with 52.5% achieving normosmia by Week 16.

  • 3

    The mean objective olfactory score increased significantly from 3.05 to 11.35, while nasal polyp scores decreased from 4.03 to 1.63.

  • 4

    Olfactory recovery was consistent across subgroups, regardless of baseline IgE levels, eosinophil counts, or previous sinus surgery.

  • 5

    Higher baseline polyp burden correlated with faster early improvement in olfactory function, but did not affect the final recovery outcomes.

Original Source(s)

Related Content